MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
暂无分享,去创建一个
C. Miller | S. Frye | J. M. Shields | B. Midkiff | J. Tentler | H. Earp | S. Moschos | R. Hamilton | Xiaodong Wang | Jing Liu | Weihe Zhang | D. DeRyckere | D. Graham | S. Eckhardt | M. Sambade | L. Duncan | Chao Yang | J. Schlegel | N. Nikolaishvili-Feinberg | D. Trembath | S. Sather | Craig C. Carson | A. Winges | Pei-Fen Kuan | A. Tan
[1] A. Pierce,et al. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology , 2012, Oncogene.
[2] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[3] W. Franklin,et al. Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer , 2012, Oncogene.
[4] H. Chu,et al. A prognostic signature of defective p53‐dependent G1 checkpoint function in melanoma cell lines , 2012, Pigment cell & melanoma research.
[5] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[6] Ken Dutton-Regester,et al. Reviewing the somatic genetics of melanoma: from current to future analytical approaches , 2012, Pigment cell & melanoma research.
[7] D. DeRyckere,et al. Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus , 2012, PloS one.
[8] S. Frye,et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. , 2012, ACS medicinal chemistry letters.
[9] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[10] P. Mischel,et al. Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway , 2011, PloS one.
[11] G. Castellano,et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. , 2011, The Journal of investigative dermatology.
[12] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[13] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[14] R. Halaban,et al. Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma , 2011, Molecular Cancer Research.
[15] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[16] J. M. Shields,et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] Jonathan Chernoff,et al. Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .
[18] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[19] Dennis B. Troup,et al. NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..
[20] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[21] A. Thorburn,et al. Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity , 2010, Molecular Cancer Therapeutics.
[22] D. Elder,et al. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study , 2010, Journal of cutaneous pathology.
[23] Buu P. Tu,et al. A genomic screen identifies TYRO3 as a MITF regulator in melanoma , 2009, Proceedings of the National Academy of Sciences.
[24] B. Dahlbäck,et al. Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival , 2009, Clinical Cancer Research.
[25] S. Eschrich,et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis , 2008, BMC Medical Genomics.
[26] R. Marais,et al. Melanoma biology and new targeted therapy , 2007, Nature.
[27] B. Varnum,et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. , 2007, Blood.
[28] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] H. Snodgrass,et al. Ectopic Expression of the Proto-oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia , 2006, Clinical Cancer Research.
[30] J. Kirkwood,et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.
[31] H. Kung,et al. Signal Pathways in Up-regulation of Chemokines by Tyrosine Kinase MER/NYK in Prostate Cancer Cells , 2004, Cancer Research.
[32] C. Springer,et al. V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.
[33] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[34] D. Rimm,et al. Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.
[35] R. Scott,et al. Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.
[36] Amy Lynnette Van Deusen,et al. Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia , 2012 .
[37] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[38] H. Earp,et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.
[39] N. Dubrawsky. Cancer statistics , 2022 .